TRINITY BIOTECH PLC — Form F-1/A
Filed August 21, 2026 · analyzed by the Registration Agent
F-1/A
▼ Likely negative
significance 28/100
What the filing says
Trinity Biotech PLC terminated its Standby Equity Purchase Agreement with YA II PN, LTD., effective July 7, 2026, which had provided an option to sell up to $25 million in ADSs. As a result, 675,048,580 ordinary shares (1,125,081 ADSs post-split) remain registered but unsold and are now being removed from registration. The company had previously executed a 1-for-30 reverse ADS split on July 24, 2026, converting the ADS ratio from 1:20 to 1:600 ordinary shares.
Why this rating
Termination eliminates $25M liquidity backstop; company size unknown but facility was material option. Reverse split typically signals distress. Routine removal of unsold shares from registration, but loss of funding cushion is concerning.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.